MindBio Therapeutics Corp. has started the pre-screening process to select participants for its Phase 2 clinical trial on LSD-Microdosing as a treatment for Major Depressive Disorder, making it the first time that take-home approvals have been given for LSD-Microdosing in a clinical trial.
The initial Phase 2a open-label trial will last for 8 weeks and aims to evaluate the effectiveness of LSD-Microdosing in improving sleep quality, mood, creativity, social connectivity, and energy levels among patients with Major Depressive Disorder.
Previous trials conducted by MindBio Therapeutics have shown positive outcomes, including enhanced sleep quality and subjective feelings of well-being, creativity, happiness, social connectivity, and energy in participants who received LSD-Microdosing. These individuals also reported decreased feelings of anger and irritability.
MindBio has developed exclusive formulations and safe delivery